Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
VCEL
HoldPremium GrowerVericel Corporation · Healthcare · United States · $2.1B · Avg Vol: $18M/d
COMPANY DESCRIPTION
Vericel Corporation is a commercial-stage biotechnology company specializing in advanced autologous cell therapies for severe medical conditions, primarily focusing on knee cartilage repair (MACI) and burn care (Epicel, NexoBrid). The company maintains a leading position in these niche markets due to its proprietary manufacturing processes, strong clinical evidence, and the high regulatory barriers inherent in cell therapy. Vericel acts as a pioneer in regenerative medicine with a highly specialized product portfolio.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 164.4M | 197.5M | 237.2M | 276.3M | 18.9% | 306.3M | 336.2M | 392.9M | 19.3% |
| EPS | -0.16 | -0.35 | -0.07 | 0.21 | 0.33 | 57.1% | 0.48 | 0.53 | — | 61.3% |
| Shares | — | 47.3M | 47.8M | 49.6M | 50.6M | +7.1% | 51.2M | — | — | — |
| Debt | — | 47.6M | 88.0M | 99.0M | 96.4M | 26.5% | 93.1M | — | — | — |
| Equity | — | 192.3M | 226.0M | 292.0M | 354.6M | 22.6% | — | — | — | — |
| Op CF | — | 17.7M | 35.3M | 58.2M | 51.9M | 43.2% | 69.7M | — | — | — |
| Inv CF | — | -36.2M | -3.1M | -79.0M | -43.9M | — | — | — | — | — |
| Fin CF | — | 1.0M | 3.6M | 19.1M | 7.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VCEL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VCEL | Vericel Corporation(you) | $2.1B | 56 | Hold |
| ADMA | ADMA Biologics, Inc. | $2.1B | 53 | Hold |
| URGN | UroGen Pharma Ltd. | $2.1B | 51 | Hold |
| FTRE | Fortrea Holdings Inc. | $1.8B | 60 | Hold |
| SEPN | Septerna, Inc. | $1.8B | 52 | Hold |
| SRPT | Sarepta Therapeutics, Inc. | $2.2B | 46 | Hold |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.0B | 50 | Hold |
| OMER | Omeros Corporation | $1.3B | 48 | Hold |
| SLS | SELLAS Life Sciences Group, Inc. | $2.7B | 44 | Hold |
| TARS | Tarsus Pharmaceuticals, Inc. | $3.1B | 44 | Hold |
Peer medians: ROE -30.8% · P/E 26.9x · Gross margin 58.1%